Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | OPRM1 | P35372 | 13/20 | 0.56 |
| ▸ | OPRD1 | P41143 | 5/20 | 0.41 |
| ▸ | OPRK1 | P41145 | 4/20 | 0.39 |
| ▸ | SIGMAR1 | Q99720 | 5/20 | 0.38 |
| ▸ | ADRA2A | P08913 | 1/20 | 0.36 |
| ▸ | AR | P10275 | 1/20 | 0.36 |
| ▸ | PTGS1 | P23219 | 1/20 | 0.36 |
| ▸ | SLC6A2 | P23975 | 1/20 | 0.36 |
| ▸ | HTR2A | P28223 | 1/20 | 0.36 |
| ▸ | ADRA1A | P35348 | 1/20 | 0.36 |
| ▸ | PTGS2 | P35354 | 1/20 | 0.36 |
| ▸ | SLC6A3 | Q01959 | 1/20 | 0.36 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.36 |
| ▸ | SCN5A | Q14524 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5754114 | 0.86 | OPRM1 (0.39) | OPRM1OPRD1OPRK1 | |
| SCHEMBL5754398 | 0.83 | OPRM1 (0.41) | OPRM1OPRD1OPRK1 | |
| SCHEMBL5751643 | 0.77 | OPRM1 (0.66) | OPRM1OPRD1OPRK1SIGMAR1ADRA2A | |
| SCHEMBL7965735 | 0.77 | OPRM1 (0.66) | OPRM1OPRD1OPRK1SIGMAR1ADRA2A | |
| SCHEMBL5753435 | 0.77 | OPRM1 (0.66) | OPRM1OPRD1OPRK1ADRA2AAR | |
| SCHEMBL5754673 | 0.77 | OPRM1 (0.66) | OPRM1OPRD1OPRK1SIGMAR1ADRA2A | |
| SCHEMBL5754744 | 0.74 | OPRM1 (0.57) | OPRM1OPRD1SIGMAR1 | |
| SCHEMBL5754727 | 0.74 | OPRM1 (0.62) | OPRM1OPRD1OPRK1SIGMAR1 | |
| SCHEMBL5753484 | 0.71 | OPRM1 (1.00) | OPRM1OPRD1OPRK1KCNH2 | |
| SCHEMBL5754694 | 0.71 | OPRM1 (0.83) | OPRM1OPRD1OPRK1KCNH2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1140828-B1 | 3-AZABICYCLO¬3.1.0|HEXANE DERIVATIVES AS OPIATE RECEPTORS LIGANDS | PFIZER LTD (GB) | 2006-08-09 | — | — | EP | claimed |
| EP-1140828-B1 | 3-AZABICYCLO¬3.1.0|HEXANE DERIVATIVES AS OPIATE RECEPTORS LIGANDS | PFIZER LTD (GB) | 2006-08-09 | — | — | EP | disclosed |
| US-7049444-B2 | 3-azabicyclo[3.1.0]hexane derivatives useful in therapy | PFIZER INC. (US) | 2006-05-23 | — | — | US | disclosed |
| US-20030013875-A1 | 3-azabicyclo[3.1.0]hexane derivatives useful in therapy | PFIZER, INC. (US) | 2003-01-16 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20030013875-A1 | 3-azabicyclo[3.1.0]hexane derivatives useful in therapy | OPRM1, OPRK1, OPRD1 | OPRM1 1/4885OPRD1 3/4885OPRK1 2/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.